Qure.ai recently closed a $65 million Series D funding round. This round was led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital. Existing investors, including Novo Holdings and HealthQuad, also contributed.
The funds will be used to accelerate Qure.ai’s expansion into the US and other markets, bolster investments in foundational AI models, and enable strategic acquisitions of MedTech companies to strengthen their offerings.
Emphasising on the significance of Artificial Intelligence (AI) in overcoming healthcare bottlenecks, Prashant Warier, Co-Founder and Chief Executive Officer (CEO), stated, “Our work helps unlock clinical efficiencies and raises the standard of care for patients, globally.”
Warier also noted the company’s role in accelerating the early diagnosis and treatment of critical diseases, particularly through collaboration with industry leaders.
The latest funding will drive further innovation, enabling Qure.ai to scale its impact worldwide and improve healthcare outcomes for under-served populations.
Founded in 2016 by Prashant Warier, Qure.ai partners with global healthcare organisations with a mission to make healthcare more accessible through AI solutions.
